![[Updated] B-2 Spirit Bombers Struck Iranian Nuclear Sites](https://theaviationist.com/wp-content/uploads/2025/06/B2sGuam_2.jpg)
Novo Nordisk’s amylin obesity drug keeps performing like Zepbound
Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not be the standout treatment that investors had hoped for.
Novo previously reported that patients on CagriSema lost 20% of their weight in a 68-week Phase 3 trial when looking at all participants, a similar level of weight loss seen in Zepbound studies.
